Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Return on Capital Employed (2021 - 2023)

Historic Return on Capital Employed for Cullinan Therapeutics (CGEM) over the last 3 years, with Q3 2023 value amounting to 0.37%.

  • Cullinan Therapeutics' Return on Capital Employed fell 6000.0% to 0.37% in Q3 2023 from the same period last year, while for Sep 2023 it was 0.37%, marking a year-over-year decrease of 6000.0%. This contributed to the annual value of 0.3% for FY2022, which is 5200.0% up from last year.
  • Latest data reveals that Cullinan Therapeutics reported Return on Capital Employed of 0.37% as of Q3 2023, which was down 6000.0% from 0.33% recorded in Q2 2023.
  • Cullinan Therapeutics' Return on Capital Employed's 5-year high stood at 0.31% during Q2 2022, with a 5-year trough of 0.37% in Q3 2023.
  • For the 3-year period, Cullinan Therapeutics' Return on Capital Employed averaged around 0.01%, with its median value being 0.03% (2021).
  • Examining YoY changes over the last 5 years, Cullinan Therapeutics' Return on Capital Employed showed a top increase of 4700bps in 2023 and a maximum decrease of -6400bps in 2023.
  • Over the past 3 years, Cullinan Therapeutics' Return on Capital Employed (Quarter) stood at 0.16% in 2021, then soared by 263bps to 0.26% in 2022, then tumbled by -244bps to 0.37% in 2023.
  • Its Return on Capital Employed stands at 0.37% for Q3 2023, versus 0.33% for Q2 2023 and 0.22% for Q1 2023.